Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

245.59 -1.16 (-0.47%)
Streaming Delayed Price Updated: 12:07 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,791,134
Open 245.75
Bid (Size) 245.52 (400)
Ask (Size) 245.61 (100)
Prev. Close 246.75
Today's Range 243.18 - 246.30
52wk Range 141.50 - 251.71
Shares Outstanding 2,628,679,824
Dividend Yield 2.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"
As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire

Performance

YTD
+18.4%
+18.4%
1 Month
+6.4%
+6.4%
3 Month
+19.6%
+19.6%
6 Month
+37.9%
+37.9%
1 Year
+46.8%
+46.8%

More News

Read More
News headline image
How to Spot Winning Innovation ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap? ↗
Via The Motley Fool
News headline image
2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash ↗
Via The Motley Fool
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock ↗
Via The Motley Fool
News headline image
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector ↗
Via MarketBeat
News headline image
Is Johnson & Johnson Stock Outperforming the Nasdaq?
Via Barchart.com
Topics Stocks World Trade
News headline image
Kenvue Defies Market Headwinds with Q4 Earnings Beat as Kimberly-Clark Merger Looms
Via MarketMinute
Topics Earnings Economy World Trade
News headline image
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio ↗
Via The Motley Fool
Topics Retirement
News headline image
The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson ↗
Via The Motley Fool
News headline image
Economic Stagnation: Q4 2025 GDP Misses Mark as Government Shutdown Hangs Heavy Over 2026 Outlook
Via MarketMinute
Topics Earnings Economy
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B ↗
Via Stocktwits
News headline image
Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
From Johnson & Johnson
Via Business Wire
News headline image
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer ↗
Via Benzinga
News headline image
Behind the Scenes of Johnson & Johnson's Latest Options Trends ↗
Via Benzinga
News headline image
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner ↗
Via Benzinga
News headline image
The Seven-Thousand Siege: S&P 500’s Historic Breach and the Great Tech Pivot of 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
News headline image
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer ↗
Via Benzinga
News headline image
Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial
From Beasley Allen Law Firm
Via Business Wire

Frequently Asked Questions

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded.
What exchange does Johnson & Johnson trade on?
Johnson & Johnson trades on the New York Stock Exchange
What is the ticker symbol for Johnson & Johnson?
The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange
What is the current price of Johnson & Johnson?
The current price of Johnson & Johnson is 245.59
When was Johnson & Johnson last traded?
The last trade of Johnson & Johnson was at 03/04/26 12:07 PM ET
What is the market capitalization of Johnson & Johnson?
The market capitalization of Johnson & Johnson is 645.58B
How many shares of Johnson & Johnson are outstanding?
Johnson & Johnson has 646B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.